Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA Trial

被引：82

作者：

Apter, Dan ^{[1
]}

Wheeler, Cosette M. ^{[2
,3
]}

Paavonen, Jorma ^{[4
]}

Castellsague, Xavier ^{[5
]}

Garland, Suzanne M. ^{[6
,7
]}

Skinner, S. Rachel ^{[8
,9
]}

Naud, Paulo ^{[10
]}

Salmeron, Jorge ^{[11
,12
]}

Chow, Song-Nan ^{[13
]}

Kitchener, Henry C. ^{[14
]}

Teixeira, Julio C. ^{[15
]}

Jaisamram, Unnop ^{[16
]}

Limson, Genara ^{[17
]}

Szarewski, Anne ^{[18
]}

Romanowski, Barbara ^{[19
]}

Aoki, Fred Y. ^{[20
]}

Schwarz, Tino F. ^{[21
,22
]}

Poppe, Willy A. J. ^{[23
]}

Xavier Bosch, F. ^{[24
]}

Mindel, Adrian ^{[25
]}

De Sutter, Philippe

Hardt, Karin ^{[26
,27
]}

Zahaf, Toufik ^{[26
,27
]}

Descamps, Dominique ^{[26
,27
]}

Struyf, Frank ^{[26
,27
]}

Lehtinen, Matti ^{[28
]}

Dubin, Gary ^{[29
]}

机构：

[1] Sexual Hlth Clin, Family Federat Finland, Helsinki, Finland

[2] Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Albuquerque, NM 87131 USA

[3] Univ New Mexico, Hlth Sci Ctr, Dept Obstet & Gynecol, Albuquerque, NM 87131 USA

[4] Univ Helsinki, Dept Obstet & Ginecol, Helsinki, Finland

[5] Hosp Llobregat, Biomed Res Ctr Network Epidemiol & Publ Hlth CIBE, DIBELL, ICO,Canc Epidemiol Res Program, Catalonia, Spain

[6] Univ Melbourne, Royal Womens Hosp, Murdoch Childrens Res Inst, Microbiol & Infect Dis Dept, Melbourne, Vic, Australia

[7] Univ Melbourne, Murdoch Childrens Res Inst, Dept Obstet & Gynaecol, Melbourne, Vic, Australia

[8] Telethon Inst Child Hlth Res, Vaccine Trials Grp, Perth, WA, Australia

[9] Univ Sydney, Childrens Hosp Westmead, Discipline Paediat & Child Hlth, Sydney, NSW 2006, Australia

[10] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil

[11] Inst Mexicano Seguro Social, Unidad Invest Epidemiol, Cuernavaca, Morelos, Mexico

[12] Inst Mexicano Seguro Social, Serv Salud, Cuernavaca, Morelos, Mexico

[13] Natl Taiwan Univ, Coll Med & Hosp, Dept Obstet & Gynecol, Taipei 10764, Taiwan

[14] St Marys Hosp, Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester M13 0JH, Lancs, England

[15] Univ Estadual Campinas, Campinas, SP, Brazil

[16] Chulalongkorn Univ, Fac Med, Dept Obstet & Gynaecol, Bangkok 10330, Thailand

[17] Univ Philippines, Philippine Gen Hosp, Coll Med, Makati Med Ctr, Makati, Philippines

[18] Queen Mary Univ London, Ctr Canc Prevent, Wolfson Inst Prevent Med, London, England

[19] Univ Alberta, Edmonton, AB, Canada

[20] Univ Manitoba, Winnipeg, MB, Canada

[21] Univ Wurzburg, Acad Teaching Hosp, Stiftung Juliusspital, Cent Lab, Wurzburg, Germany

[22] Univ Wurzburg, Acad Teaching Hosp, Stiftung Juliusspital, Vaccinat Ctr, Wurzburg, Germany

[23] Univ Hosp KU Leuven Gasthuisberg, Dept Gynaecol, Leuven, Belgium

[24] Network Cooperat Canc Res RTICC, Inst Catala Oncol, IDIBELL, Canc Epidemiol Res Program, Catalonia, Spain

[25] Ctr AIDS Programme Res Soth Africa, Durban, South Africa

[26] Vrije Univ Brussel, Univ Ziekenhuis Brussel, Afdelingshoofd Gynaecol Oncol, Brussels, Belgium

[27] GSK Vaccines, Wavre, Belgium

[28] Univ Tampere, Sch Publ Hlth, FIN-33101 Tampere, Finland

[29] GSK Vaccines, King Of Prussia, PA USA

来源：

CLINICAL AND VACCINE IMMUNOLOGY | 2015年 / 22卷 / 04期

关键词：

OF-STUDY ANALYSIS; PARTICLE VACCINE; HPV-VACCINATION; FOLLOW-UP; TYPE-16; CANCER; PREVALENCE; SAFETY; IMMUNIZATION; PREVENTION;

D O I：

10.1128/CVI.00591-14

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We report final event-driven analysis data on the immunogenicity and efficacy of the human papillomavirus 16 and 18 ((HPV16/18) AS04-adjuvanted vaccine in young women aged 15 to 25 years from the PApilloma TRIal against Cancer In young Adults (PATRICIA). The total vaccinated cohort (TVC) included all randomized participants who received at least one vaccine dose (vaccine, n = 9,319; control, n = 9,325) at months 0, 1, and/or 6. The TVC-naive (vaccine, n = 5,822; control, n = 5,819) had no evidence of high-risk HPV infection at baseline, approximating adolescent girls targeted by most HPV vaccination programs. Mean follow-up was approximately 39 months after the first vaccine dose in each cohort. At baseline, 26% of women in the TVC had evidence of past and/or current HPV-16/18 infection. HPV-16 and HPV-18 antibody titers postvaccination tended to be higher among 15- to 17-year-olds than among 18- to 25-year-olds. In the TVC, vaccine efficacy (VE) against cervical intraepithelial neoplasia grade 1 or greater (CIN1+), CIN2+, and CIN3+ associated with HPV-16/18 was 55.5% (96.1% confidence interval [CI], 43.2, 65.3), 52.8% (37.5, 64.7), and 33.6% (-1.1, 56.9). VE against CIN1+, CIN2+, and CIN3+ irrespective of HPV DNA was 21.7% (10.7, 31.4), 30.4% (16.4, 42.1), and 33.4% (9.1, 51.5) and was consistently significant only in 15- to 17-year-old women (27.4% [10.8, 40.9], 41.8% [22.3, 56.7], and 55.8% [19.2, 76.9]). In the TVC-naive, VE against CIN1+, CIN2+, and CIN3+ associated with HPV-16/ 18 was 96.5% (89.0, 99.4), 98.4% (90.4, 100), and 100% (64.7, 100), and irrespective of HPV DNA it was 50.1% (35.9, 61.4), 70.2% (54.7, 80.9), and 87.0% (54.9, 97.7). VE against 12-month persistent infection with HPV-16/18 was 89.9% (84.0, 94.0), and that against HPV-31/33/45/51 was 49.0% (34.7, 60.3). In conclusion, vaccinating adolescents before sexual debut has a substantial impact on the overall incidence of high-grade cervical abnormalities, and catch-up vaccination up to 18 years of age is most likely effective.

引用

页码：361 / 373

页数：13

共 44 条

[1] Introducing HPV vaccine in developing countries - Key challenges and issues [J].

Agosti, Jan M. ;

Goldie, Sue J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (19) :1908-1910

[2]

American Society for Colposcopy and Cervical Pathology, 2014, GUID RES

[3]

[Anonymous], 2012, INTRO HPV VACCINES E

[4] The causal relation between human papillomavirus and cervical cancer [J].

Bosch, FX ;

Lorincz, A ;

Muñoz, N ;

Meijer, CJLM ;

Shah, KV .

JOURNAL OF CLINICAL PATHOLOGY, 2002, 55 (04) :244-265

[5] HPV prevalence, viral load and physical state of HPV-16 in cervical smears of patients with different grades of CIN [J].

Briolat, Jenny ;

Dalstein, Veronique ;

Saunier, Maellle ;

Joseph, Karine ;

Caudroy, Stephanie ;

Pretet, Jean-Luc ;

Birembaut, Philippe ;

Clavel, Christine .

INTERNATIONAL JOURNAL OF CANCER, 2007, 121 (10) :2198-2204

[6] A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women [J].

Brown, DR ;

Shew, ML ;

Qadadri, B ;

Neptune, N ;

Vargas, M ;

Tu, WZ ;

Juliar, BE ;

Breen, TE ;

Fortenberry, JD .

JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (02) :182-192

[7] The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women [J].

Carter, JJ ;

Koutsky, LA ;

Wipf, GC ;

Christensen, ND ;

Lee, SK ;

Kuypers, J ;

Kiviat, N ;

Galloway, DA .

JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (05) :927-936

[8] Long-term persistence of anti-HPV-16 and-18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses [J].

David, Marie-Pierre ;

Van Herck, Koen ;

Hardt, Karin ;

Tibaldi, Fabian ;

Dubin, Gary ;

Descamps, Dominique ;

Van Damme, Pierre .

GYNECOLOGIC ONCOLOGY, 2009, 115 (03) :S1-S6

[9] Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study [J].

de Sanjose, Silvia ;

Quint, Wim G. V. ;

Alemany, Laia ;

Geraets, Daan T. ;

Ellen Klaustermeier, Jo ;

Lloveras, Belen ;

Tous, Sara ;

Felix, Ana ;

Eduardo Bravo, Luis ;

Shin, Hai-Rim ;

Vallejos, Carlos S. ;

Alonso de Ruiz, Patricia ;

Lima, Marcus Aurelho ;

Guimera, Nuria ;

Clavero, Omar ;

Alejo, Maria ;

Llombart-Bosch, Antonio ;

Cheng-Yang, Chou ;

Alejandro Tatti, Silvio ;

Kasamatsu, Elena ;

Iljazovic, Ermina ;

Odida, Michael ;

Prado, Rodrigo ;

Seoud, Muhieddine ;

Grce, Magdalena ;

Usubutun, Alp ;

Jain, Asha ;

Hernandez Suarez, Gustavo Adolfo ;

Estuardo Lombardi, Luis ;

Banjo, Aekunbiola ;

Menendez, Clara ;

Javier Domingo, Efren ;

Velasco, Julio ;

Nessa, Ashrafun ;

Chichareon, Saibua C. Bunnag ;

Qiao, You Lin ;

Lerma, Enrique ;

Garland, Suzanne M. ;

Sasagawa, Toshiyuki ;

Ferrera, Annabelle ;

Hammouda, Doudja ;

Mariani, Luciano ;

Pelayo, Adela ;

Steiner, Ivo ;

Oliva, Esther ;

Meijer, Chris J. L. M. ;

Al-Jassar, Waleed Fahad ;

Cruz, Eugenia ;

Wright, Thomas C. ;

Puras, Ana .

LANCET ONCOLOGY, 2010, 11 (11) :1048-1056

[10] Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention A pooled analysis of 11 clinical trials [J].

Descamps, Dominique ;

Hardt, Karin ;

Spiessens, Bart ;

Izurieta, Patricia ;

Verstraeten, Thomas ;

Breuer, Thomas ;

Dubin, Gary .

HUMAN VACCINES, 2009, 5 (05) :332-340

← 1 2 3 4 5 →